HawkScreener
Register Sign In
Dashboard Screener Heatmap Compare Sign In

TCMD

Tactile Systems Technology, Inc. (NASDAQ)

Healthcare — Medical Devices

Tactile Systems Technology, Inc., a medical technology company, develops and provides medical devices to treat underserved chronic diseases in the United States. It offers Flexitouch Plus system, a pneumatic compression device for the treatment of lymphedema, phlebolymphedema, lipedema, venous insufficiencies, and other types of edema and leg ulcers; Entre Plus System, a pneumatic compression device for the at-home treatment of lymphedema, chronic edema, venous insufficiency, and chronic wounds. The company also provides Nimbl, a pneumatic compression platform for the treatment of upper extremity lymphedema; Kylee, a mobile application to help patients learn about lymphedema, track their symptoms, and treatment, as well as to share their progress with their doctor; and AffloVest, a portable high frequency chest wall oscillation vest to treat patients with retained pulmonary secretions resulting from bronchiectasis, cystic fibrosis, and various neuromuscular disorders. Tactile Systems Technology, Inc. was incorporated in 1995 and is headquartered in Minneapolis, Minnesota.

None 4 analysts
$30.87
+$0.22 (+0.72%)
Target: $39.50 (28.0%)
Sign in to add TCMD to a watchlist or set price alerts.

Price History

52-Week Range

Fundamentals

Market Cap$696.31M
P/E Ratio (TTM)35.48
Forward P/E20.51
EPS (TTM)$0.87
Dividend Yield-
Profit Margin5.91%
Revenue Growth22.80%
ROE9.59%
Debt/Equity6.97
Recommendation None
Analyst Target$39.50
Analysts4
Indexes NASDAQ

Technical Indicators

RSI (14)79.7
Beta0.83
SMA 20-
SMA 40-
52-Week High$37.77
52-Week Low$9.42
50-Day Avg$25.34
200-Day Avg$24.58
Avg Volume302.9K
Volume4.2K

Performance Analysis

BULLISH

TCMD shows predominantly bullish signals based on its fundamentals and technicals.

+ Showing strength at 76% of its 52-week range.
- RSI at 79.7 indicates overbought conditions — a pullback may be due.
+ Price is above both the 50-day and 200-day moving averages — strong uptrend.
+ Strong revenue growth of 22.8% year-over-year.
~ Wall Street consensus is "none" from 4 analysts.
+ Average analyst target of $39.50 implies 28.0% upside.

Recent News

Loading news...
Sign in for full analysis Unlock insider trading data, options chain, news feed, and more.
Sign In

Last updated: Jul 02, 2026 13:33 UTC

Back to Screener Export Report